- Service Name
TransIT®-AAViator Transfection System
- Industry
Life Sciences, Biotechnology, Gene Therapy, Transfection Technology
- Main Value Proposition
The primary value offered is the ability to significantly enhance AAV production efficiency, leading to better outcomes in gene therapy applications.
- Description
The TransIT®-AAViator Transfection System is designed specifically for maximizing AAV production, offering enhanced transfection efficiency. It is complemented by the RevIT™AAV Enhancer, which boosts AAV titers significantly across various conditions.
- Key Features
2-4X Higher Titers with RevIT™AAV Enhancer; Tailored for maximal AAV production; Supports various serotypes and cell lines; Nucleic acid delivery powered by intentional design
- Use Cases
Primary scenarios include producing viral vectors for clinical and commercial applications, manufacturing recombinant proteins, and conducting gene editing studies using CRISPR.
- Competitive advantages
Higher transfection efficiency leading to increased AAV titers; Specialized support for various serotypes and cell lines; Proven track record in therapeutic viral vector manufacturing
- Strengths
Key strengths include a long history of innovation in transfection technology, a focus on low cellular toxicity, and a commitment to enhancing the efficiency of gene delivery systems.
- Positioning
The service positions itself as a leader in transfection technology, specifically for AAV production, catering to the needs of the biopharmaceutical industry.
- Audience
The target users include researchers in gene therapy, biopharmaceutical companies, and academic institutions focused on advanced therapeutic development.
- CTA
Get started
- Tags
Transfection
AAV Production
Gene Therapy
Nucleic Acid Delivery
- Tagline
Take your titers to new heights with a transfection system tailored specifically for maximal AAV production
- Tone of Voice
Professional, Innovative, Supportive
- Differentiation
This service is unique in its focus on intentional design for nucleic acid delivery, specifically tailored for AAV production, which sets it apart from generic transfection systems.
- Brand Positioning
Mirus Bio is positioned as a pioneering life science company dedicated to improving nucleic acid delivery systems, emphasizing innovation and efficiency.
- Founded
1995-01-01
- Founders
James Hagstrom
Jon Wolff
Vladimir Budker